Associate Professor Michelle Tate is an emerging leader in the fields of viral pathogenesis and immunology. After completing her PhD studies at the University of Melbourne in 2010, Michelle was recruited to the Centre for Innate Immunity and Infectious Diseases. A/Prof Tate is currently a NHMRC Career Development Fellow and since 2017 has led the Viral Immunity and Immunopathology research group.
A/Prof Tate’s research interests lie primarily in understanding the molecular mechanisms and pathways involved in the development of hyperinflammation and severe disease, particularly during influenza A virus infection. Critically, she has made significant contributions to understanding viral pathogenesis including the identification of new therapeutic targets and treatment strategies. A/Prof Tate’s research has been published in top virology, immunology and multidisciplinary journals such as PLoS Pathogens, Immunity, eLife, Journal of Immunology, Journal of Virology, British Journal of Pharmacology and Scientific Reports. In addition, A/Prof Tate productively collaborates with a number of commercial partners to facilitate the development of novel anti-inflammatory drugs for influenza, COVID-19, as well as respiratory diseases such as silicosis.
In recognition of her achievements, A/Prof Tate has been awarded an NHMRC Project and Ideas Grants, an MRFF grant, as well as NHMRC Early Career and Career Development Fellowships. A/Prof Tate has received numerous national and international awards, including a Young Tall Poppy Science Award (2018), the Christina Fleischmann Memorial Award (International Cytokine and Interferon Society 2016), Victorian Infection and Immunity Network Career Development Award (2016) and a Commendation for the Victorian Premier’s Award for Health and Medical Research (2011). Her research has been acknowledged by invitations to present at international and national meetings. In addition, A/Prof Tate is a member of the Journal of Virology, Virology Journal, Pathogens and Frontiers Viral Immunology editorial boards.
Rosli S, Kirby FJ, Lawlor KE, Rainczuk K, Drummond GR, Mansell A, Tate MD (2019) Repurposing drugs targeting the P2X7 receptor to limit hyperinflammation and disease during influenza virus infection. British J Pharm. 176(19):3834-3844.
Pinar A, Dowling JK, Bitto NJ, Robertson AA, Latz E, Stewart CR, Drummond GR, Cooper MA, McAuley JL, Tate MD*, Mansell A* (2017) PB1-F2 Peptide Derived from Avian Influenza A Virus H7N9 Induces Inflammation via Activation of the NLRP3 Inflammasome. J Biol Chem 292(3):826-836 * equal senior author.
Kedzierski L*, Tate MD*, Hsu AC*, Kolesnik TB, Linossi EM, Dagley L, Dong Z, Freeman S, Infusini G, Starkey MR, Bird NL, Chatfield SM, Babon JJ, Huntington N, Belz G, Webb A, Wark PA, Nicola NA, Xu J, Kedzierska K, Hansbro PM, Nicholson SE (2017) Suppressor of cytokine signaling (SOCS)5 ameliorates influenza infection via inhibition of EGFR signaling. Elife. e20444. * equal contribution.
Ong JD, Mansell A, Tate MD (2017) Hero turned villain: NLRP3 inflammasome-induced inflammation during influenza A virus infection. J Leukoc Biol 101(4):863-874.
Tate MD, Ong JD, Dowling JK, McAuley JL, Robertson AB, Latz E, Drummond GR, Cooper MA, Hertzog PJ, Mansell A (2016) Reassessing the role of the NLRP3 inflammasome during pathogenic influenza A virus infection via temporal inhibition. Sci Rep 6:27912.
Tate MD, Job ER, Deng YM, Gunalan V, Maurer-Stroh S, Reading PC (2014) Playing hide and seek: how glycosylation of the influenza virus hemagglutinin can modulate the immune response to infection. Viruses 6:1294-1316.
Thomas BJ, Porritt RA, Hertzog PJ, Bardin PG, Tate MD (2014) Glucocorticosteroids enhance replication of respiratory viruses: effect of adjuvant interferon. Sci Rep 4:7176.
McAuley JL, Tate MD, MacKenzie-Kludas CJ, Pinar A, Zeng W, Stutz A, Latz E, Brown LE, Mansell A (2013) Activation of the NLRP3 inflammasome by IAV virulence protein PB1-F2 contributes to severe pathophysiology and disease. PLoS Pathog 9:e1003392.
Tate MD, Brooks AG, Reading PC, Mintern JD (2012) Neutrophils sustain effective CD8+ T-cell responses in the respiratory tract following influenza infection. Immunol Cell Biol 90:197-205.
Tate MD, Brooks AG, Reading PC (2011) Specific sites of N-linked glycosylation on the hemagglutinin of H1N1 subtype influenza A virus determine sensitivity to inhibitors of the innate immune system and virulence in mice. J Immunol 187:1884-1894.
Tate MD, Ioannidis LJ, Croker B, Brown LE, Brooks AG, Reading PC (2011) The role of neutrophils during mild and severe influenza virus infections of mice. PLoS One 6:e17618.
Tate MD, Job ER, Brooks AG, Reading PC (2011) Glycosylation of the hemagglutinin modulates the sensitivity of H3N2 influenza viruses to innate proteins in airway secretions and virulence in mice. Virology 413:84-92.
Tate MD, Pickett DL, van Rooijen N, Brooks AG, Reading PC (2010) Critical role of airway macrophages in modulating disease severity during influenza virus infection of mice. J Virol 84:7569-7580.
Tate MD, Deng YM, Jones JE, Anderson GP, Brooks AG, Reading PC (2009) Neutrophils ameliorate lung injury and the development of severe disease during influenza infection. J Immunol 183:7441-7450.